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Abstract
Alternative splicing of pre-mRNA is a mechanism that increases the protein diversity of a single gene by differential exon
inclusion/exclusion during post-transcriptional processing. While alternative splicing is established to occur during
lymphocyte activation, little is known about the role it plays during the immune response. Our study is among the first
reports of a systematic genome-wide analysis of activated human T and B lymphocytes using whole exon DNA microarrays
integrating alternative splicing and differential gene expression. Purified human CD2
+ T or CD19
+ B cells were activated
using protocols to model the early events in post-transplant allograft immunity and sampled as a function of time during
the process of immune activation. Here we show that 3 distinct classes of alternatively spliced and/or differentially
expressed genes change in an ordered manner as a function of immune activation. We mapped our results to function-
based canonical pathways and demonstrated that some are populated by only one class of genes, like integrin signaling,
while other pathways, such as purine metabolism and T cell receptor signaling, are populated by all three classes of genes.
Our studies augment the current view of T and B cell activation in immunity that has been based exclusively upon
differential gene expression by providing evidence for a large number of molecular networks populated as a function of
time and activation by alternatively spliced genes, many of which are constitutively expressed.
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Introduction
The technology for investigating gene expression in cells and
tissues has developed significantly over the last decade, making
global gene expression profiling using microarrays relatively
straightforward. However, until recently, the field has concentrat-
ed largely on studies of differential gene expression and
discovering signatures that correlate with various biological
challenges or disease states. Unfortunately, the premise of
analyzing differential gene expression is limited by the view that
molecular mechanisms or biomarkers are represented by classes of
genes either up- or down-regulated in a given situation. Alternative
splicing (AS) is a process by which a single pre-mRNA transcript
can give rise to multiple protein isoforms through the mechanism
of coordinated intron removal and differential exon joining. AS is
a major source of diversity in the human proteome; as many as
75% [1,2] of all human genes are alternatively spliced and the
most recent study using next-generation sequencing technology
indicates that 92–94% of human genes undergo alternative
splicing [3,4]. Splicing can modulate protein function by changing
functional domains, affinities for assembly of heteromeric
complexes, or altering mRNA stability. The advent of high-
throughput genomics has dramatically changed the view of
alternative splicing from a single gene perspective to the level of
genome-wide discovery and quantification.
A major challenge in medicine is a molecular understanding of
the immune response in conditions that range from autoimmune
diseases such as Type I diabetes mellitus and multiple sclerosis to
organ and cell transplantation. While there has been a steady
progress in unraveling the complexities of innate and adaptive
cellular immunity, there remain many unknowns particularly in
our understanding of immune regulation and signaling networks
that shape the course and outcome of lymphocyte activation.
There are many reports of genome-wide differential gene
expression of lymphocytes [5–27]. In contrast, literature for
genome-wide alternative splicing in any system is still limited and,
while AS is established to occur during lymphocyte activation,
little is known about the role AS plays in immunity [25,28–32].
One advance is the Affymetrix Human Exon 1.0 ST arrays that
allow a high-throughput, genome-wide approach to analyze both
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chip. Human Exon 1.0 ST arrays have specific oligonucleotide
probes for essentially every known and predicted exon in the latest
build of the human genome. A number of publications exist for
the use of these arrays in genome-wide gene expression analysis
[33–45], four of which included analysis of alternative splicing
[34,35,46,47] in the context of cancer cells. However, presently
there are only a few papers on activation-dependent genome-wide
alternative splicing in human T lymphocytes, using the Agilent
44K microarray platform that allows monitoring of .5000
cassette-type AS events in human cells [28], as well as Exon 1.0
ST array to study the genome-wide effect of silencing a splicing
factor during T cell activation [48].
The present study is among the first to report a systematic
genome-wide analysis integrating alternative splicing and differ-
ential gene expression with analysis of functional molecular
networks populated during human lymphocyte activation. We
used the Human Exon 1.0 ST array platform to integrate the
analysis of genome-wide gene expression with alternative splicing
as a function of time during activation of purified human CD2+ T
cells or purified CD19+ B cells. We detected 3 distinct classes of
genes in both T and B cells that changed as a function of immune
activation: 1) differentially expressed and alternatively spliced, 2)
constitutively expressed and alternatively spliced, and 3) differen-
tially expressed without alternative splicing.
Approximately 60% or more of all the alternatively spliced
genes in T cells are differentially expressed at the mRNA
transcript level during activation and only 25–30% of B cell
transcripts. However, analysis of constitutively expressed tran-
scripts demonstrated that 50–70% in T cells and about 40% in B
cells are alternatively spliced. These results demonstrate the
significant increase in transcriptional diversity generated by
alternative splicing during lymphocyte activation and emphasize
how large the relative contribution to this diversity is made by
alternative splicing of constitutively expressed genes. Finally, we
mapped the three classes of genes to functional molecular
networks. These studies expand the current view of T and B cell
activation in immunity that has been based exclusively upon
differential gene expression by providing evidence for a large
number of molecular networks populated as a function of time and
activation by alternatively spliced genes.
Results
Differential Gene Expression and Alternative Splicing in
Activated Lymphocytes
We wanted toidentifychangesinglobal transcript expression and
alternative splicing (AS) as a function of activation of primary
human T and B lymphocytes. We purified T and B cells using
magnetic bead-coupled CD2 and CD19 antibodies, respectively. T
cells were activated using anti-CD3/CD28 beads and B cells were
activated with anti-CD40 antibody cross-linked by anti-IgG plus
rIL2 and rIL10. We confirmed cell activation by looking at known
activation marker expression with multi-channel parallel FACS at 0
and 48 hours post activation. T48 hours was selected for activation
marker analysis from previous observations that showed the peak of
activation by 48 hours (data not shown). For T cells, many
differences were observed between stimulated and control T cells:
after activation for 48 hours, activation markers were higher,
chemokine receptors werelow, cytokine producingcellswerehigher
and many other marked changes were present, representative of T
cell activation. Higher levels (relative intensity) of activation markers
on CD4+ T cells were observed for CD134 (OX40), CD150
(SLAM), CD25 (IL-2Ra), CD69 (early activation marker), and
CD71 (transferin receptor) at 48 hours compared to unactivated
cells. Also, a higher fraction of stimulated CD4+ T cells were
positive for these activation markers: CD134 (78%), CD150 (50%),
CD25 (90%), CD69 (95%), and CD71 (80%). We also observed
higher levels of these activation markers on stimulated CD8+ T cells
and higher fraction of stimulated CD8+ T cells were positive for
these same activation markers. We also detected lower levels of
chemokine receptors CCR5, CD183 (CXCR3), and CD197
(CCR7) on stimulated CD4+ and CD8+ T cells compared to
resting. Both CD4+ and CD8+ T cells expressed lower levels of
CD127 (IL-7 receptor a chain) after stimulation. We also observed
much higher intensities for such cytokines as IFNc, IL-2 and TNFa
intensities on stimulated CD4+ T cells compared to control CD4+
T cells, where they were almost undetectable. A higher fraction of
stimulated CD4+ T cells produced IFNc, IL-2, and TNFa as
determined by intracellular cytokine staining while no detectable
IL-10 or IL-4 producing cells were detected in either control or
stimulated CD4+ T cells. We observed similar results for stimulated
CD8+ T cells compared to resting CD8+ T cells. (See Figure S1,
Table S1 and Table S2).
B cells stimulated for 48 hours showed some levels (mean
channel intensity above 200) of positive staining for activation
markers CD150, CD25, and CD69, whereas resting B cells do not
express these markers (mean channel intensity,100). Stimulated B
cells showed significantly higher levels of positive staining for co-
stimulatory molecules CD54, CD80, CD86 compared to resting B
cells. Resting B cells are typically positive for CD21 and CD62L
whereas we only observed 40% of stimulated B cells that were
positive for these markers consistent with the fact that CD21 and
CD62L are shed during B cell activation. (Figure S2 and Table
S1 and Table S2).
Total RNA and protein was extracted at 0, 24, 48 and 72 hours
post activation. Both differential gene expression and alternative
splicingweredetected usingAffymetrixHumanExon1.0STArrays
that are comprised of different probes designed to interrogate all the
known exon sequences inthe currentversion of the human genome.
The Exon array results were analyzed using the bioinformatics tool,
XRAY, which identifies the alternative use of specific exons in each
gene detected between multiple time points.
As shown in Table 1, the total number of detected AS genes is
significantly higher at all time points in T cells compared to B cells.
This is also true for the subset of genes that are annotated as
alternatively spliced in the public domain of RefSeq. Based on a
parallel analysis of mRNA transcript levels and alternative exon
usage, we observed two classes of AS genes: 1) differentially
expressed (AS+DE) and, 2) constitutively expressed (AS+CE). We
also identified a separate third class of genes that are differentially
expressed (DE) but show no evidence of alternative splicing.
Next, taking all the annotated, AS genes, we compared the
relative numbers of constitutively and differentially expressed
transcripts. The point of this comparison is that activation-
dependent changes in cell function can be caused by AS even if the
transcript’s absolute expression is unchanged. During T cell
activation, there are comparable numbers of AS+DE and AS+CE
genes. In contrast, the opposite is true for B cell activation in which
the number of AS+CE genes is consistently higher. Finally, the
majority of differentially expressed genes in both T and B cell
activation are up-regulated (79% to 92%; Table 1).
Alternatively Spliced Genes in T Cell Activation Are Either
Differentially or Constitutively Expressed
The first class of AS genes comprise those that are both alternatively
spliced and differentially expressed (AS+DE). First, the total numbers of
AS+DE genes at 24, 48 and 72 hours are significantly greater during T
Alternate Splicing in Immunity
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activation (222, 260, 95, respectively) (Table 1). Second, in these
primary activated human T cells approximately 60% or more of all the
alternatively spliced genes are also differentially expressed at the
mRNA transcript level at all points during the course of activation.
These results contrast sharply with data from an analysis of AS in an
activated human T cell line, Jurkat, that found that the majority of AS
genes do not demonstrate differential expression [28]. The difference
could be due to the choice of cells (primary T cells vs. Jurkat), the
activation method (anti-CD28/CD3 vs. PMA) or the technology
(Agilent 44K AS arrays).
There are 353 AS+DE genes common to all 3 activation time
points in T cells, which we propose are genes involved in the entire
process of T cell activation (Figure 1a). Six of the top ten
canonical pathways identified with Ingenuity Pathway Analysis
(IPA) are signaling via IL-6, IL-10, p38 MAPK, T cell receptors,
death receptors and apoptosis (Figure 1b). Next, we analyzed
genes detected as AS+DE but unique to each time point (1102,
288 and 171 genes at 24, 48 and 72 hours, respectively), which we
propose are time-specific drivers of activation. Surprisingly, the
canonical pathways identified at all three time points are largely
involved in cell metabolism rather than pathways typically linked
to immunity (Figure 1c–e). On the other hand, activation is a
cellular process, whether it is driven by immunity, inflammation or
any other mechanism. The most populated pathway is purine
metabolism present at all three time points (28, 14, and 10 genes at
24, 48 and 72 hours, respectively). It is important to emphasize
that these represent 52 different genes sequentially expressed and
alternatively spliced as a function of time in a single pathway.
Finally, there is third subset of AS+DE genes that are shared
between two activation times (640 at 24 and 48 hours) and (113 at
48 and 72 hours), which we propose are genes that are involved in
the transitions between events in activation marked by the specific
time points (Figure 1a). Pathway analysis of these shared AS+DE
genes revealed both immune/inflammatory mechanisms such as
ERK/MAPK, glucocorticoid receptor and IL-2 signaling and
metabolic pathways such as pyrimidine, propanoate and glycine,
serine and threonine metabolism (Figure 1f). In effect, the
canonical functions of these AS+DE genes that are shared between
the transition time points are a mix of the elements found in the
AS+DE genes unique or common to all time points.
The second class of AS genes comprise those that are alternatively
spliced but constitutively expressed (AS+CE) as a function of
activation (Table 1). For example, from a total of 2,328 constitutively
expressed genes at 24 hours, we detected 1702 that were alternatively
spliced (73%). This is remarkable because the typical approach to
gene expression profiling experiments is to exclude the constitutively
expressed genes from further analysis. While 230 AS+CE genes were
shared at all three time points after activation, functional pathway
analysis did not reveal any specific themes (Figure 2a). In contrast,
analysis of the AS+CE genes unique to the three time points revealed
a prevalence of canonical pathways linked to immune/inflammation
including T cell receptor, PI3K/AKT, integrin and death receptor/
apoptosis signaling at 24 hours and JAK/Stat, SAPK/JNK, TGFb,
and interferon signaling at 48 hours (Figure 2c–e). The third subset
of AS+CE genes are those shared between the transition time points.
F o re x a m p l e ,f o r2 4v s .4 8h o u r s ,t h e r ea r e5 9 4A S +CE genes
identified that are linked to a large number of canonical pathways
associated with immune/inflammatory activation including signaling
by IL-4, GM-CSF, insulin, IGF-1, PDGF, and via PI3K/AKT
(Figure 2f).
A literature search for genes that are experimentally validated to
be AS in T cells or hematopoietic lineage cells under any
conditions revealed only 41 genes (Table S3). At 24 hours, we
detected 21 of the known AS genes, 17 of which were called as AS
by XRAY analysis. At 48 hours, we detected expression 25 known
AS genes, 13 of which were called as AS (p,0.001; Table 2) and
17 of which were shared with the known genes identified at
24 hours (data not shown). Seven of these 25 genes were also
detected in activated B cells at 48 hours. Finally, at 72 hours, we
detected expression of 13 known AS genes, 6 of which were called
as AS by XRAY analysis. Overall, we detected 29 of the 41 known
AS genes in the literature (71%) during the course of activating T
cells.
Given the large number of AS genes identified by our analysis at
48 hours in activated T cells (1394 AS+DE and 1730 AS+CE;
Table 1), we analyzed the gene expression of known or putative
splicing factors at the same time point. Of 25 splicing factors
expressed in activated T cells at 48 hours, 15 showed significant
differential gene expression (p,0.001) and 11 were alternatively
spliced (p,0.001; Table S4). Interestingly, the majority of
splicing factors that are alternatively spliced are not differentially
expressed (80%). In agreement with prior observations [28,49], the
majority of splicing factors with significant differential gene
expression were up-regulated by activation. The same analysis
revealed 11 known splice factors in activated B cells at 48 hours,
10 of which were also detected in T cells with the same expression
patterns (Table S4).
Genes That Are Differentially Expressed but Not
Alternatively Spliced during T Cell Activation
After T cell activation, there are 2524, 1762 and 1065
differentially expressed (DE) genes where no AS was detected at
24, 48 and 72 hours, respectively (Figure 3a). Of these, 643 genes
Table 1. Detectable differential gene expression and alternative splicing changes in activated lymphocytes.
Cell
type
Hours
post
activation
Alternatively spliced
genes (% genes
detected)
Alternatively spliced
genes with differential
gene expression (% total
differentially expressed)
Alternatively spliced genes
with constitutive gene
expression (% total
constitutively expressed)
Differentially expressed
genes with no alternative
splicing (% up-regulated)
Constitutively
expressed genes
(% genes detected)
T 24 3,863 (54%) 2161 (46%) 1702 (73%) 2,473 (86%) 2328 (33%)
T 48 3,154 (55%) 1394 (44%) 1760 (69%) 1,761 (88%) 2547 (45%)
T 72 1,584 (45%) 703 (41%) 881 (49%) 1,027 (83%) 1783 (51%)
B 24 991 (47%) 222 (63%) 769 (44%) 131 (92%) 1747 (83%)
B 48 967 (42%) 260 (46%) 707 (41%) 310 (87%) 1722 (75%)
B 72 973 (44%) 96 (41%) 877 (44%) 140 (79%) 1990 (89%)
doi:10.1371/journal.pone.0007906.t001
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7906Figure 1. Canonical pathways for alternatively spliced and differentially expressed T cell genes (p,0.001) shows both immune/
inflammatory mechanisms and metabolism. (A) Venn diagram representing the alternatively spliced and differentially expressed (AS+DE) genes
detected at 24, 48, and 72 hours in activated T cells, with total number of detected genes per time point shown in parenthesis, number of genes
unique to each time point shown by the number inside the circle and number of genes shared between time points in the shaded overlapping areas,
with number of genes detected at all three time points shown in the central overlap. (B–F) Pie charts representing the Ingenuity Pathway Analysis
output for the top canonical pathways populated by AS+DE genes during T cell activation: (B) shared at all time points, (C) genes unique to 24 hour
time-point, (D) genes unique to the 48 hour time-point, (E) genes unique to the 72 hour time-point, (F) genes uniquely detected during the transition
between 24 and 48 hour time-points. Numbers next to pathway name indicate the number of detected genes that are assigned to each pathway.
The size of each shaded slice is proportional to the number of genes per pathway compared to total number of genes per chart.
doi:10.1371/journal.pone.0007906.g001
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PLoS ONE | www.plosone.org 4 November 2009 | Volume 4 | Issue 11 | e7906Figure 2. Alternatively spliced/constitutively expressed T cell genes (p,0.001) unique to each activation time-point populate
canonical pathways for immune/inflammation. (A) Venn diagram representing the alternatively spliced/constitutively expressed (AS+CE) genes
detected at 24, 48, and 72 hours in activated T cells, with total number of detected genes per time point shown in parenthesis, number of genes
unique to each time point shown by the number inside the circle and number of genes shared between time points in the shaded overlapping areas,
with number of genes detected at all three time points shown in the central overlap. (B–F) Pie charts representing the Ingenuity Pathway Analysis
output for the top canonical pathways populated by AS+CE genes during T cell activation: (B) shared at all time points, (C) genes unique to 24 hour
time-point, (D) genes unique to the 48 hour time-point, (E) genes unique to the 72 hour time-point, (F) genes uniquely detected during the transition
between 24 and 48 hour time-points. Numbers next to pathway name indicate the number of detected genes that are assigned to each pathway.
The size of each shaded slice is proportional to the number of genes per pathway compared to total number of genes per chart.
doi:10.1371/journal.pone.0007906.g002
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number of canonical pathways linked to immune/inflammatory
networks includingsignalingvia T cell receptors, Toll-likereceptors,
PI3K/AKT, IL-6, IL-2, IL-10, p38 MAPK, PDGF, acute phase
response and glucocorticoid receptors (Figure 3b). However, there
are also multiple pathways representing metabolic networks
including pyrimidine, purine, protein ubiquitination, glycolysis/
gluconeogenesis, aryl hydrocarbon receptor signaling and aminoa-
cyl-tRNA biosynthesis. There are 1086 genes uniquely DE at
24 hours (Figure 3c), the peak of gene expression for T cell
activation. The four highest ranked pathways (.20 genes/pathway)
are purine metabolism, protein ubiquitination, NRF2-mediated
oxidative stress response and glucocorticoid receptor signaling. It is
notable that between the DE genes unique at 24 hours and those
DE genes common at all three time points, we can populate the
canonical pathway for protein ubiquitination with 38 different
genes, 46 for purine metabolism and 44 for glucocorticoid receptor
signaling. In combination with the 52 AS+DE genes populating the
purine metabolism pathway already described above, we have
identified a totalof98 differentgenesinthis singlepathwayof a total
of 418 known genes in the pathway as listed in Ingenuity (23%).
RT-PCR and RNA Deep Sequencing Validation of Predicted
AS Events Confirms 19 New AS Gene Candidates in Activated
T Cells
We ranked and filtered the entire list of AS candidate genes
predicted by the XRAY analysis of our whole exon array data
based on the FDR corrected p values determined by ANOVA for
alternative probe set usage. From the list of candidates with
statistically significant alternative probe set usage (p val-
ues,0.001), we then selected 32 candidate AS genes at random,
not previously known in the literature to be alternatively spliced in
activated T cells. The splicing events predicted in these 32
candidate genes included cassette exons, mutually exclusive exons,
bleeding exons, intron retention, alternative start sites, and
alternative UTRs (see Table 3 and Table S5 for primer and
probe set information). Primers were designed to target flanking,
constitutively expressed and RefSeq annotated exons. RT-PCR
was performed for individual total RNA samples from 8 of the 10
donors used in the generation of the whole exon array data
comparing the activation of T cells at T0 and T48 hours.
Alternative splicing was also tested in parallel by deep
sequencing of total RNA from activated T cells of 3 donors at
Table 2. Detected known T cell alternatively spliced genes at 48 hrs post activation.
Gene Symbol Gene Annotation
Max. fold-
change
Differential gene expression
ANOVA P value (FDR corrected)
Alternative exon usage ANOVA
P value (FDR corrected)
ILF3 interleukin enhancer binding factor 3 90 kDa 1.21 2.96E-01 2.42E-15
MAP4K4 mitogen-activated protein kinase kinase kinase
kinase 4
21.21 8.57E-02 1.81E-12
CD44* CD44 molecule (Indian blood group) 1.01 1.00E+00 8.52E-09
FKBP2* FK506 binding protein 2 13 kDa 2.01 4.65E-05 1.53E-07
MAP4K1 mitogen-activated protein kinase kinase kinase
kinase 1
1.31 1.19E-01 1.05E-06
CUGBP2 CUG triplet repeat RNA binding protein 2 21.11 1.00E+00 1.13E-06
FKBP8 FK506 binding protein 8 38 kDa 1.81 1.09E-03 1.72E-06
IRAK1 interleukin-1 receptor-associated kinase 1 1.31 2.42E-04 1.68E-05
FKBP11 FK506 binding protein 11 19 kDa 21.11 1.00E+00 5.31E-05
FKBP1A FK506 binding protein 1A 12 kDa 1.91 3.31E-06 6.24E-05
LEF1 lymphoid enhancer-binding factor 1 21.51 6.03E-01 1.50E-04
ICAM1 intercellular adhesion molecule 1 (CD54) human
rhinovirus receptor
2.01 6.64E-06 1.55E-04
FKBP3* FK506 binding protein 3 25 kDa 1.81 1.69E-03 8.08E-04
IRF1 interferon regulatory factor1 21.81 5.12E-03 1.01E-03
FYN FYN oncogene related to SRC FGR YES 1.61 8.50E-02 2.51E-03
CD79B CD79b molecule immunoglobulin-associated b 1.11 1.00E+00 2.83E-03
GATA3 GATA binding protein 3 1.31 7.69E-05 1.43E-02
CLK2 CDC-like kinase 2 1.71 2.08E-03 9.38E-02
SYK spleen tyrosine kinase 21.11 1.01E-04 1.20E-01
IL2 interleukin 2 7.31 1.24E-08 1.00E+00
HRB* HIV-1 Rev binding protein 2.91 4.40E-06 1.00E+00
HMMR* hyaluronan-mediated motility receptor (RHAMM) 3.11 4.59E-09 1.00E+00
HIF1A* hypoxia-inducible factor 1 alpha subunit
(basic helix-loop-helix transcription factor)
3.61 2.39E-06 1.00E+00
FKBP4* FK506 binding protein 4 59 kDa 4.41 8.70E-07 1.00E+00
CTLA4 cytotoxic T-lymphocyte-associated protein 4 7.41 1.32E-08 1.00E+00
*Also detected in B cells at 48 hours, with FKBP4 and HRB predicted to be alternatively spliced and HMMR and FKBP2 to be also differentially up-regulated.S e e
supplemental Table S1 for complete list of known AS genes.
doi:10.1371/journal.pone.0007906.t002
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PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7906Figure 3. T cell genes differentially expressed (p,0.001) but without splicing that are common to all time-points populate a mix of
immune/inflammation and metabolic pathways. (A) Venn diagram representing the differentially expressed genes with no alternative splicing
(DE) detected at 24, 48, and 72 hours in activated T cells, with total number of detected genes per time point shown in parenthesis, number of genes
unique to each time point shown by the number inside the circle and number of genes shared between time points in the shaded overlapping areas,
with number of genes detected at all three time points shown in the central overlap. (B–E) Pie charts representing the Ingenuity Pathway Analysis
output for the top canonical pathways populated by DE genes during T cell activation: (B) shared at all time points, (C) genes unique to 24 hour time-
point, (D) genes unique to the 48 hour time-point, (E) genes unique to the 72 hour time-point. Numbers next to pathway name indicate the number
of detected genes that are assigned to each pathway. The size of each shaded slice is proportional to the number of genes per pathway compared to
total number of genes per chart.
doi:10.1371/journal.pone.0007906.g003
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analyzed the sequencing results using the GenomeStudio RNA
Sequencing Module (Illumina, Inc., San Diego, CA) that also
allowed us to visualize the aligned reads and analyze results of
exon counts, genes and splice junctions found in our data. These
data are shown in Figure 4a for 24 candidate genes. We totaled
the exon counts in GenomeStudio for all the known exons of each
of the 32 candidate genes for validation for 3 donors at T0 vs.
T48 hours of activation. These results were then compared to
XRAY whole exon array results and 19/32 (59%) candidate
Table 3. Differentially alternatively spliced candidate genes selected from the Whole Exon Gene Array and RNA-Seq data for RT-
PCR validation in activated T cells between 0 and 48 hours.
Gene Probe Set ID
Probe Set
exon
Expressed
p-value
1
AS PS
p-value
2 F
3 R
3
Alternative Splicing
Event
4
XRAY 1.0ST exon
call (DT48/T0)
5
RNA Seq exon counts
(DT48/T0, 3/3 donors)
6
TNFAIP3 2927516 Int4 4.56E-37 8.38E-04 3 5 intron Inclusion Lower Splicing Increased(3/3)
TA-NFKBH 3860131 Ex3 4.25E-08 4.71E-04 2 6 cassette exon Higher Splicing Not detected (3/3)
TA-NFKBH 3860129 Ex4 1.39E-07 2.60E-04 2 6 cassette exon/alt-39 Higher Splicing Decreased (2/3)
CDC42 2324660 Ex7 4.43E-29 9.89E-04 6 7/8 mutually exclusive exon Higher Splicing Decreased(1/3), Increased 2/3
HSPA14 3236409 Ex4 1.65E-07 2.74E-06 1 5 cassette exon Higher Splicing Decreased (2/3)
GZMB 3558395 Ex1 6.15E-27 6.24E-09 1 3 alternative 59 UTR Higher Splicing Decreased (1/3) Increased (2/3)
CLASP1 2573699 Ex24 4.29E-06 2.85E-05 21 25 cassette exon Higher Splicing Undetected(1/3), Increased (2/3)
LYK5 3766291 Ex11ext 1.38E-37 1.36E-06 9 11b mutually exclusive exon Higher Splicing Decreased (1/3), Increased (2/3)
LYK5 3766290 Ex11ext 1.16E-17 7.27E-04 9 11b mutually exclusive exon Higher Splicing Decreased (1/3), Increased (2/3
CDCA5 3377433 Ex4 8.86E-42 1.68E-07 3 5 cassette exon Lower Splicing Not detected (3/3)
ILF17 2957120 Ex2 1.13E-24 1.98E-06 1 3 alternative 59 UTR Higher Splicing Not detected (2/3), Increased (1/
3)
CSF1 2351093 Ex6ext 2.53E-20 1.14E-06 5 8 mutually exclusive exon Higher Splicing Not detected (1/3), Increased (1/
3), Decreased (1/3)
CREM 3242380 Ex8a 1.90E-29 5.85E-04 7 9 cassette exon Lower Splicing Not detected (1/3), Increased (1/
3), Decreased (1/3)
WDR51A 2675975 E8 6.62E-10 4.74E-06 7 9b cassette exon Higher Splicing Decreased (1/3), Undetected (2/
3)
UNC45A 3608546 E10 2.03E-20 6.41E-05 9 11 cassette exon Lower Splicing Increased (1/3), Undetected (2/3)
TUBA1A 3453838 E4 1.05E-48 5.56E-08 4 4 alt-C-term Higher Splicing Decreased (3/3)
TUBA1A 3453839 E4 2.86E-59 1.25E-07 4 4 alt-C-term Higher Splicing Decreased (3/3)
TIMM50 3833104 E6 1.47E-34 1.07E-05 2 7 bleeding exon Higher Splicing Increased (2/3)
SLC25A3 3427827 E2 5.25E-24 2.62E-06 1c-2 4 cassette exon Higher Splicing Increased (1/3), Decreased (1/3),
Undetected (1/3)
RUNX1 3930438 E1 9.21E-41 4.29E-05 1 3 bleeding exon Lower Splicing Decreased (2/3) Increased (1/3)
RUNX1 3930435 E1 3.09E-19 7.32E-10 1 3 bleeding exon Lower Splicing Decreased (2/3) Increased (1/3)
RUNX1 3930436 E1 2.61E-37 7.34E-08 1 3 bleeding exon Lower Splicing Decreased (2/3) Increased (1/3)
RBBP6 3653318 E1 1.14E-35 7.32E-05 1 5 cassette exon Higher Splicing Decreased (2/3)
RBBP6 3653319 E1 4.56E-25 1.57E-04 1 5 cassette exon Higher Splicing Decreased (2/3)
RBBP6 3653326 E3 6.47E-51 1.39E-04 1 5 cassette exon Higher Splicing Decreased (2/3)
RBBP6 3653335 E4 7.31E-23 4.56E-04 1 5 cassette exon Higher Splicing Not Detected
NLN 2812388 E9 4.35E-15 8.17E-04 8 10 alt 59UTR/bleeding exon Higher Splicing Not Detected
NCAPD3 3399565 E29 5.19E-30 2.08E-08 28 30 cassette exon Higher Splicing Not Detected
NAB2 3417820 E2 2.13E-35 1.73E-05 2 5 alternate 59 End Lower Splicing Increased (2/3)
KIF4A 3980562 E2 6.34E-25 7.40E-11 1 3 bleeding exon/retained
intron
Higher Splicing Increased (1/3), Undetected (2/3)
ING3 3021135 E5 1.72E-19 3.75E-06 4 5 alt-C-term/bleeding exon Higher Splicing Decreased (3/3)
CDC27 3760685 E1 7.49E-42 9.73E-08 1 3 alternative 59 UTR Higher Splicing Increased (1/3), Undetected (2/3)
CDC27 3760684 E1 6.82E-21 9.58E-08 1 3 alternative 59 UTR Higher Splicing Increased (1/3), Undetected (2/3)
1ANOVA p-value for Probe Set expression as calculated by XRAY.
2ANOVA p-value for alternative Probe Set usage (alternative splicing) as calculated by XRAY.
3Exons in which the F (forward) and R (reverse) PCR primers are located.
4Known Alternative Splicing Events for the detected Probe Set shown in the UCSC Genome browser.
5Change in alternative splicing as calculated by XRAY analysis at 48 vs 0 hours (activation at 48 hours).
6Change in exon counts (number of reads that align to the exon) as observed from the RNA-Seq data at T48 vs T0 hours. Abbreviations: Ex = exon, Int = Intron, Ext =
extended exon, alt-C-term = alternative C terminal, alt-39 = alternate 3
doi:10.1371/journal.pone.0007906.t003
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PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7906Figure 4. Validation of differentially alternatively spliced gene candidates in activated T cells between 0 and 48 hours. (A)
GenomeStudio view of 24 of 32 total candidate AS genes, 17 validated by PCR and 7 candidates chosen as examples of those that were not PCR
validated. Genomic stacked alignment plots with top 3 rows representing samples 3 to 1 (top to bottom) at T0 and bottom 3 rows representing
samples 3 to 1 at T48, respectively. The y-axis represents the number of reads and the height of each bar is determined by calculating the
overlapping sequence tags for each base-pair in a 4 pixel wide region and taking the maximum value. Splice junctions, when shown, are indicated by
the grey dotted lines. Exons of interest are bordered by red vertical lines. Ensemble transcript splice variants are shown below for known annotated
splice isoforms. (B) RT-PCR validation of 24 of 32 total candidate AS genes, 17 validated by PCR and 7 candidates chosen as examples of those that
were not PCR validated. PCR was performed with primers to the neighboring constitutively expressed exons and the products were resolved on 2.5%
agarose gels. Gene symbols are listed on the right, time points and donor for each sample are listed in the top 2 panels, and observations of splice
events for indicated exons are given to the right (incl = exon retained, skip = exon spliced). Star next to a gene name indicates that the validation
results did not show the predicted splice variants. 100 bp ladder is visualized in the left-most lane. Unmarked bands most likely represent minor
splice variants, heteroduplexes or RT-PCR artifacts.
doi:10.1371/journal.pone.0007906.g004
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donor (Table S5).
The RT-PCR results validate distinct alternative splicing of the
predicted isoforms for 17 of the 32 candidates (Figure 4b and
Table 3). RT-PCR for alternatively splicing is known to be prone
to artifacts [35,47] with more bands than predicted appearing on
the gel as seen for several of our candidates (e.g. TA-NFKBH,
HSPA14). These unlabeled bands are thought to represent
heteroduplexes of the two AS isoforms [35,47]. We observed
some donor-to-donor variability for HSPA14, CLASP1, LYK5,
ILF17, NCAPD3, SLCO4A1, WDR51A, and UNC45A, which is
to be expected, as alternative splicing is likely to fluctuate among
different individuals due to the intrinsic variability in response to
lymphocyte activation and potentially genetic differences. We were
unable to validate the predicted splice isoforms for 15 of the 32
candidates (examples shown for CDCA5, ILF17, CSF1, CREM,
NLN) because we failed to simultaneously detect both the spliced
and unspliced variants required as the frame of reference necessary
to validate the AS. For example, CSF1 demonstrates only a single
PCR product at the molecular weight of the highly spliced exon 6c
variant, which is nonetheless still consistent with the higher
splicing predicted by XRAY for T48 hours (Table 3; Figure 4).
For CDCA5 there is a single RT-PCR product at T48 hours
consistent with the unspliced form of exon 4 also as predicted by
XRAY. The deep sequencing data provides an additional set of
data for reference and while limited to 3 donors, it confirms to
some degree the splicing predictions of XRAY for 14 of the 32
candidate genes (Table S5 and Table 3).
Additional Validation of Alternative Splicing during T Cell
Activation by Proteomics
We used tandem mass spectrometry proteomics (MudPIT; see
Methods) to analyze and validate alternative splicing in T cells at
0 hrs and 48 hrs post activation. We detected a total of 1510
unique proteins. The full list was searched for proteins with
multiple detected isoforms representing alternative splicing. We
found 1091 proteins (72%) with 2 or more isoforms. Based on
Table 1, the percentage of AS transcripts was 54% at 24 hours
and 55% at 48 hours.
By matching protein and transcript identifications (i.e. pro-
scripts), there are 190 AS+DE proscripts and 247 AS+CE
proscripts (Table S6). We confirmed that multiple protein
isoforms were detected in both these groups consistent with the
alternative splicing predicted by the whole exon array data: 64/
190 (34%) AS+DE and 119/247 (48%) AS+CE proscripts. We
found that 2 of our 32 candidate genes for validation were
proscripts detectable at both T0 and T48 and both were validated
by the proteomic data (GZMB and CDC27). Of the remaining
1073 proteins that were not paired with whole exon array-detected
transcripts, 825 (77%) had multiple isoforms detected by mass
spectrometry. We also observed 317 proscripts that had between 2
and 9 different isoforms detected by proteomics but that were not
predicted to be alternatively spliced by the whole exon array data.
Canonical Pathways Populated by All Three Classes of
Genes
In the context of all the different functional networks that we
have discussed for T cell activation, we found a subset of
canonical pathways that were populated as a function of time
after activation by genes representing all three classes: AS+DE,
AS+CE and DE, alone. As shown in Table 4,t h e r ea r e9
pathways where these genes populate from 15 to 50% of the total
known genes for that pathway. Using the top pathway, T cell
receptor signaling, as an example, it is evident that every level of
the signal pathway from the cell surface to the nucleus is
represented (Figure 5).
Functions of Alternatively Spliced and Differentially
Expressed Genes Demonstrates Different Networks for T
and B Cell Activation at 48 Hours Post Activation
While the major focus of this work has been on T cell activation,
we compared the top canonical pathways identified in T cells for
AS+DE, AS+CE and DE genes to those in B cells at the 48-hour
time point. For this purpose we used the total genes comprising
each class as shown in Table 5. While many T cells pathways are
linked to known immune/inflammatory networks, the majority of
the top B cell pathways are linked to cell growth, survival and
metabolism. Nonetheless, several canonical pathways populated
by all three classes of genes are shared between activated T and B
cells that reflect their common lymphocyte lineage. These are
genes linked to cell cycle G1/S checkpoint, (9 genes), G2/M DNA
damage checkpoint regulation (7 genes), as well as signaling via
aryl hydrocarbon receptor (15 genes), apoptosis (6 genes), death
receptors (8 genes) and VEGF (3 genes).
Discussion
Despite many recent reports on alternative splicing, studies of
genome-wide alternative splicing in the immune system are still
limited and, while alternative splicing (AS) is established to occur
during lymphocyte activation, little is known about the role AS
Table 4. Top canonical pathways populated by genes representing all three classes.
Top Pathways Populated genes/total in pathway (%) T24 unique T48 unique T72 unique Shared
T Cell Receptor Signaling 52/105 (49.5%) 13DE, 8AS+CE 10AS+CE N/A 9DE, 7AS+DE, 5AS+CE
Protein Ubiquitination Pathway 81/205 (39.5%) 24DE, 15AS+CE 13AS+CE 15AS+CE 14DE
Purine Metabolism 121/418 (29%) 26DE, 28AS+DE 14AS+DE 10AS+DE, 15 AS+CE 20DE, 8AS+CE
IL-10 Signaling 16/73 (22%) N/A N/A N/A 10DE, 6AS+DE
Death Receptor Signaling 14/66 (21%) 8AS+CE N/A N/A 6AS+DE
IL-6 Signaling 17/96 (17.7%) N/A N/A N/A 11DE, 6AS+DE
Glucocorticoid Receptor Signaling 44/279 (16%) 20DE N/A N/A 24DE
Integrin Signaling 31/196 (16%) 16AS+CE 15AS+CE N/A N/A
Apoptosis Signaling 14/91 (15.3%) 8AS+CE N/A N/A 6AS+DE
doi:10.1371/journal.pone.0007906.t004
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is a mechanism that increases the protein repertoire of a single
gene sequence by including or excluding exons during post-
transcriptional processing. There is evidence in different model
systems for alternative splicing of as many as 75% to 94% of all
human genes [1,2,4]. Splicing can modulate protein function by
changing functional domains, affinities for assembly of hetero-
meric complexes, or altering mRNA stability.
The majority of what we know about AS is based on
conventional single-gene approaches though more recently new
technologies to facilitate genome-wide studies have been used
[2,34,35,47,50–54]. Our study is among the first reports of a
systematic genome-wide analysis integrating AS and differential
gene expression as a function of human lymphocyte activation. In
this study, CD2
+ T and CD19
+ B lymphocytes from 10 normal
human donors were activated and sampled sequentially for 72 hrs
to model the early events in post-transplant allograft immunity.
Our hypotheses were that: 1) AS plays an important role in
regulating immunity, 2) these genes escape identification if only
differential expression is considered, and 3) identification and
mapping of AS genes to known molecular pathways is an
important first step in understanding how alternative splicing
regulates the immune response.
In this study, we have performed a quantitative analysis of
alternatively spliced exons in activated T and B lymphocytes as a
function of time after activation. Our activation protocols were
chosen to model the events in post-transplantation immune
responses where T cell activation occurs through co-stimulatory
signaling [55–57] and B cell activation involves T cell-derived
signals [12,58–65]. We used Affymetrix Human Exon 1.0 ST
arrays, a technology that permits a comprehensive and unbiased
coverage of the whole transcriptome. This approach enabled us to
perform two complementary levels of analysis: gene-level differ-
ential expression and exon-level analysis distinguishing between
different alternatively spliced isoforms of a gene. Exon-level
analysis on a whole-genome scale allows detection of specific
Figure 5. T cell receptor signaling pathway is populated by members from all three classes of genes during activation. Schematic
diagram represents the T cell receptor signaling pathway populated by the Ingenuity Pathway Analysis using genes assigned to all three classes
detected throughout the time course of activation. Shapes in green represent the class of genes with differential expression without alternative
splicing (DE). Shapes in red represent the class of genes that are alternatively spliced with constitutive gene expression (AS+CE). Shapes in blue
represent genes both alternatively spliced and differentially expressed (AS+DE). Legend for Ingenuity-Mapped Interactions: A = Activation, C =
Causes/Leads to, CP = Chemical-Protein Interaction, EC = Enzyme Catalysis, I = Inhibition, M = Biochemical Modification, P = Phosphorylation/
Dephosphorylation, PP = Protein-Protein binding, RE = Reaction, TR = Translocation. An arrow pointing from A to B signifies that A causes B to be
activated.
doi:10.1371/journal.pone.0007906.g005
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to observe differential skipping or inclusion.
Our results (Table 1) indicate that there are three detectable
classes of genes that change during the course of immune
activation in our analysis: 1) alternatively spliced and differentially
expressed (AS+DE), 2) alternatively spliced and constitutively
expressed (AS+CE), and 3) genes that are differentially expressed
but show no evidence of alternative splicing (DE). The majority of
differentially expressed genes in both T and B cell activation are
up-regulated. During T cell activation, we observed that there are
comparable numbers of AS+DE and AS+CE genes. In contrast,
the opposite is true for B cell activation in which the number of
AS+CE genes is consistently higher. Also, the total number of
detected AS genes is significantly higher at all time points in T cells
compared to B cells. These results reflect the higher level of
cellular complexity that characterize the T cells including CD4
+
and CD8
+ as well as functional T cell subsets such as Tregs and
Th17.
We observed that in primary activated human T cells at 24 and
48 hours, more than 50% of all detected genes are alternatively
spliced. However, of all the constitutively expressed genes, 73%
are alternatively spliced at 24 hours. In contrast, of all the
Table 5. Top canonical pathway genes identified by Ingenuity Network analysis in activated lymphocytes at 48 hours.
T Cells
Differential gene expression with no alternative
splicing
Differential gene expression with alternative splicing Constitutive gene expression with
alternative splicing
Aryl Hydrocarbon Receptor Signaling (32)* Apoptosis Signaling (19) Actin Cytoskeleton Signaling (45)
Glycolysis/Gluconeogenesis (22) B Cell Receptor Signaling (17) ERK/MAPK Signaling (39)
IL-6 Signaling (18) NF-kB Signaling (17) Integrin Signaling (32)
PPAR Signaling (16) SAPK/JNK Signaling 17) SAPK/JNK Signaling (31)
Cell Cycle: G1/S Checkpoint Regulation (15) p38 MAPK Signaling (14) PI3K/AKT Signaling (31)
IL-10 Signaling (14) IL-6 Signaling (13) B Cell Receptor Signaling (29)
IGF-1 Signaling (14) Death Receptor Signaling (11) Apoptosis Signaling (26)
Cell Cycle: G2/M DNA Damage Checkpoint Regulation (13) Cell Cycle: G1/S Checkpoint Regulation (8) T Cell Receptor Signaling (20)
IL-2 Signaling (11) IL-10 Signaling (8) PTEN Signaling (19)
EGF Signaling (8) Cell Cycle: G2/M DNA Damage Checkpoint Regulation (6) Fc Epsilon RI Signaling (19)
Natural Killer Cell Signaling (19)
Neurotrophin/TRK Signaling (16)
VEGF Signaling (16)
IGF-1 Signaling (16)
JAK/Stat Signaling (15)
PDGF Signaling (15)
TGF-B Signaling (15)
GM-CSF Signaling (14)
IL-4 Signaling (14)
FGF Signaling (14)
EGF Signaling (10)
IL-2 Signaling (10)
B Cells
Differential gene expression with no alternative splicing Differential gene expression with alternative splicing Constitutive gene expression with
alternative splicing
NRF2-mediated Oxidative Stress Response (10) Aryl Hydrocarbon Receptor Signaling (10) Protein Ubiquitination Pathway (15)
Protein Ubiquitination Pathway (10) Cell Cycle: G1/S Checkpoint Regulation (7) VEGF Signaling (10)
Aryl Hydrocarbon Receptor Signaling (7) p53 Signaling (6) Citrate Cycle (7)
Cell Cycle: G2/M DNA Damage Checkpoint Regulation (5) Death Receptor Signaling (5) Death Receptor Signaling (7)
Aminoacyl-tRNA Biosynthesis (5) Protein Ubiquitination Pathway (5) Pyruvate Metabolism (7)
p53 Signaling (4) Apoptosis Signaling (3) Apoptosis Signaling (7)
Antigen Presentation Pathway (3) Biosynthesis of Steroids (2) Aryl Hydrocarbon Receptor Signaling (7)
Cell Cycle: G1/S Checkpoint Regulation (3) Cell Cycle: G2/M DNA Damage Checkpoint Regulation (2) p53 Signaling (5)
Apoptosis Signaling (2) Aminoacyl-tRNA Biosynthesis (2) Nucleotide Excision Repair Pathway (4)
Endoplasmic Reticulum Stress Pathway (1) Endoplasmic Reticulum Stress Pathway (3)
*Number of molecules in each pathway.
doi:10.1371/journal.pone.0007906.t005
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24 hours. Clearly, a higher percentage of constitutively expressed
genes in T cells are alternatively spliced. This is not what we would
have expected. Our original assumption was that higher levels of
differential gene expression would correlate with higher levels of
alternative splicing. In contrast, our results suggest that in the
evolution of cellular regulation a choice has been made such that
one class of genes is primarily regulated by differential expression
during activation while another class is regulated, despite
constitutive expression, by alternatively splicing. Because the
majority of constitutively expressed genes are alternatively spliced,
there is the potential of a tremendous amount of functional gene
regulation by alternatively splicing that has not been considered
previously.
A different point is made by an analysis of the total number of
differentially and constitutively expressed genes in activated T cells
that are alternatively spliced. Because there are significantly more
differentially expressed genes in this setting, our data demonstrates
that approximately 60% or more of all the alternatively spliced
genes are differentially expressed at the mRNA transcript level and
this is true at all points during the course of activation. The
opposite seems to be true in activated B cells, where 60% or more
of all the alternatively spliced genes are constitutively expressed.
Thus, it is clear that alternative splicing is still an important
mechanism for generating complexity from the T cell’s tran-
scriptome of differentially expressed genes. Our results are in
contrast to those of another recent publication in which the
majority of alternatively spliced transcripts were not differentially
expressed [28]. These data were generated with a different array
technology and an activation protocol based on a potent cell
mitogen. We believe that our use of primary human lymphocytes
and two activation strategies specifically chosen to model natural
immune activation via T cell co-stimulation (CD3/CD28) and T
cell help for B cell activation (anti-CD40/IL2/IL10) is more
representative of biology in this context.
During T cell activation, the AS+DE genes detected and shared
at all time points are enriched in canonical pathways that reveal
immune/inflammatory mechanisms such as signaling via IL-6, IL-
10, p38 MAPK, T cell receptors, death receptors and apoptosis.
These are all canonical pathways reflecting the functional agenda of
T lymphocyte activation during an immune response. We also
observed a subset of AS+DE genes unique to each time point and
these genes populated canonical pathways representing mostly
metabolic mechanisms, with purine metabolism being the highest
populated pathway. These results are somewhat surprising and
suggest that the course of T cell activation is also driven by
regulation of selected cellular metabolic pathways. We also detected
unique AS+DE genes that marked the time point transitions (e.g. 24
to 48 hours). We propose that these genes regulate the transitions
between events occurring during activation as a function of time.
Remarkably, pathway analysis of these transition point-specific
genes revealed another set of genes that are only detected during
transitions but further populate many of the pathways already
identified and linked to both immune/inflammatory mechanisms
and metabolism. We propose that specific molecular networks are
established early in T cell activation and then additional and critical
gene components of these pathways are added as a function of time
to obtain and/or regulate the impact of these networks on the final
result. As a specific example to support these findings, we have
populated the known canonical pathway for T cell receptor
signaling using the three classes of genes we identified here:
AS+DE, AS+CE and DE, alone (Figure 5).
During T cell activation, AS+CE genes unique to each of the
three time points populate canonical pathways linked to immune/
inflammation including T cell receptor, PI3K/AKT, integrin and
death receptor/apoptosis signaling at 24 hours and JAK/Stat,
SAPK/JNK, TGFb, and interferon signaling at 48 hours. Thus, it
is evident that AS+CE genes add more members to populate the
same canonical pathways linked to AS+DE genes but also
contribute to additional pathways during activation. Similar to
what we found for the AS+DE genes, AS+CE genes that mark the
time transition points during T cell activation are linked to
predominantly different networks including signaling by IL-4,
GM-CSF, insulin, IGF-1, PDGF, and via PI3K/AKT.
We also observed the up-regulation of a large number of the
known splicing factors. A number of splicing factors were also
alternatively spliced, indicating a possibility of auto-regulatory
mechanisms involved at the level of regulating splicing. Interest-
ingly, the majority of splicing factors that are alternatively spliced
are not differentially expressed. It is a common belief that cell
activation is regulated predominantly by differential gene
expression. This belief is why essentially every paper on profiling
of cell transcriptomes during experimental or clinical events is
concentrated on identifying patterns of differential gene expression
and the pathways impacted by these changes. Thus, we thought
that alternative splicing would also follow differential gene
expression and genes associated with alternative splicing would
be changing during activation. This is clearly not the case.
An important question is how well do the results of our 1.0ST
Exon Arrays reflect the alternative splicing during B and T
lymphocyte activation? The first important point is that the results
are relatively consistent for each class of activated lymphocyte and
eachtimepoint asreflectedbythe highstatisticalvaluesweachieved
for thousands of genes with 10 donors for each time point for each
class of cells. The second point is that our conclusions for overall per
cent alternatively spliced genes (50–70%) are well in line with the
literature. A third point is that we used a tandem mass spectrometry
proteomics approach to validate alternative splicing and found over
800 alternatively spliced proscripts. Finally, we chose at random a
set of 32 candidate genes from the list of statistically significant
candidates for alternative splicing for RT-PCR validation. We
designed PCR primers to exons flanking the predicted sites of
alternative splicing. From the 32 candidate genes chosen in
activated T cells at 48 hours, we observed multiple splice variants
for 17 candidate genes. The other candidates demonstrated only a
single detectable PCR product and thus, could not be definitively
validated. To put these validation results in a proper context,
previous studies for alternative splicing validations done by PCR
range from 33% to 86% success rates [66]. Thus, our validation
success rate of 53% is within the expected range for this particular
platform and method of validation.
The tandem mass spectrometry proteomic dataset identified
317 matching transcripts/proteins (called proscripts) for which
there were multiple isoforms demonstrated consistent with
alternative splicing. A functional network analysis using Ingenuity
revealed 10 highly significant networks linked to mechanisms of
cancer, cell cycle regulation, cellular assembly, molecular transport
and cell metabolism. Several canonical pathways were highly
significantly over-represented in activated T cells (Table S7) and
included aminoacyl tRNA biosynthesis, purine metabolism, and
integrin signaling, which were also identified by the whole exon
array data analysis shown in Tables 4 and 5.
The final question is what kind of specific mechanistic insights
can we obtain by analysis of alternative splicing during lymphocyte
activation? For this purpose we discuss the potential impact of the
alternative splicing we identified in this study for 5 genes. First,
TNFAIP3 (tumor necrosis factor alpha-induced protein 3)
localized in the nucleus, is rapidly induced by Tumor Necrosis
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terminating TNF-induced NF-kappa B responses as well as
TNF-mediated apoptosis. Our analysis of the whole exon array
data, validated by PCR, indicated that the AS probe set coding for
Intron 4 is preferentially spliced out at T0 compared to T48,
resulting in intron retention at 48 hours (Table 3). The biological
consequences induced by the retention of Intron 4, including the
potential that this contributes to the protein sequence in this
important regulatory Zn-finger protein, are presently unknown.
TA-NFKBH (T-cell activation NFKB-like protein) is localized
in the nucleus and functions in the regulation of inflammatory
responses through regulation of NF-kappa-B activity. It is also
thought to regulate TCR-induced negative selection of thymo-
cytes. We identified probe sets coding for two cassette exons,
Exons 3 and 4, as alternatively spliced at 48 hours. Results of deep
RNA sequencing at T48 indicated that Exon 3 is more commonly
spliced out than Exon 4 and RT-PCR showed evidence of splicing
either exon, but almost no splicing of both at the same time. These
splicing events modify the 59UTR of the mature transcript as well
as changing part of the coding region. The coding region affected
contains 6 Ankyrin repeats that mediate protein-protein interac-
tions in very diverse families of proteins.
CDC42 (cell division cycle 42) is a small GTPase of the Rho-
subfamily that regulates signaling pathways that control cell
morphology, migration, endocytosis and cell cycle progression.
Alternative splicing of this gene is known to produce multiple
transcript variants. Our whole exon array data for T cell activation
demonstrated alternative splicing of Exon 7, which is a mutually
exclusive exon with Exon 8. This splicing changes a small part of
the coding region as well as the entire 39UTR altering the C-
terminus of the translated protein. This observation was confirmed
by PCR and the deep RNA sequencing data.
HSPA14 (heat shock 70 kDa protein 14) belongs to the family of
heat shock hsp70 proteins required for key cellular processes and
cell survival in response to environmental changes but this protein
family is incompletely characterized at this time. Our results
predict alternative splicing of Exon 4 at T48 hours of activation.
This cassette exon is in the coding region and is predicted to have
6 motifs: N-glycosylation site, Protein kinase C phosphorylation
site, Casein kinase II phosphorylation site, N-myristoylation site,
Eukaryotic thiol (cysteine) proteases histidine active site, and a
motif called heat shock hsp70 proteins family signature 3.
GZMB (granzyme 2, cytotoxic T-lymphocyte-associated serine
esterase 1) is crucial for the mechanism of cell killing induced by
cytotoxic T cells in cell-mediated immune responses. Our whole
exon array data, PCR and deep RNA sequencing data indicated
that the 59UTR and part of the coding region of Exon 1 are
alternatively spliced out during activation. Since the coding region
contains the trypsin-like serine protease domain required for the
function of granzyme B in cell killing, the alternative splicing
demonstrated here might regulate the structure and activation
capacity of the molecule as a function of T cell activation.
It is clear that the ability to identify alternative splicing at a
genome-wide level adds another dimension to our view of
lymphocyte activation. Exon arrays provide a platform for
identifying such genome-wide changes normalizing for individual
exon and gene expression between any two states in question.
However, it is critical to emphasize that mechanistic understand-
ings of alternative splicing events at this level will require
additional tools to efficiently map thousands of alternatively
spliced exons to predicted protein sequences and from sequences
to functional and regulatory domains. Thus, one point of the
present work is to provide proof of the potential value of this kind
of bioinformatics tool development for genomics and immunology.
In sum, we demonstrate that during T and B lymphocyte
activation there are three classes of genes changing as a function of
time: alternatively spliced and differentially expressed (AS+DE),
constitutively expressed and alternatively spliced (AS+CE) and
differentially expressed but not alternatively spliced (DE). We show
that some canonical pathways are populated by only one class of
genes, while other pathways, such as purine metabolism and T cell
receptor signaling, are populated by all three classes of detected
genes and these are changing in time. Our conclusion is that
differential gene expression and/or alternative splicing of specific
gene members in functional molecular networks during lympho-
cyte activation contributes to the regulation of these events.
Moreover, the potential importance of constitutively expressed
genes has been consistently ignored by previous studies of gene
expression profiling that have focused only on differential gene
expression. Our results now make it clear that the function and
impact of many constitutively expressed genes could be signifi-
cantly altered by alternative splicing events during lymphocyte
activation. These studies expand the current views of T and B
lymphocyte activation by providing evidence for a large number of
molecular networks populated as a function of time and activation
by alternatively spliced genes.
Materials and Methods
Human Lymphocyte Isolation
We purified CD2
+ T-lymphocytes and CD19
+ B-lymphocytes
from Ficoll-Hypaque density separated peripheral blood mono-
nuclear cells (PBMC) of 10 normal human donors. Miltenyi
MACS CD2
+ and CD19
+ micro-magnetic beads were used for the
positive isolation of CD2
+ T-cells and CD19
+ B cells, respectively,
using a MACS separator with LS columns (MACS, Miltenyi
Biotec).
Ex Vivo Lymphocyte Activation, RNA and Protein Extraction
Freshly isolated, resting CD2
+ T-cells were resuspended in
RPMI-1640 complete media and activated with CD3/CD28 Dynal
(Invitrogen) beads (25 ml beads to 1610
6 T cells). Cultures were
sampled at 24, 48 and 72 hrs. A subset of isolated, resting cells
immediately stabilized by RNALater (Ambion) were used as the
baseline comparison (T0). The CD3 antibody coated on the CD3/
CD28 T Cell Expander is specific for the epsilon chain of human
CD3,asubunitoftheTCRcomplex.The CD28antibodyisspecific
for the human CD28 co-stimulatory molecule, which is the receptor
for CD80 (B7-1) and CD86 (B7-2). Both antibodies are coupled to
the same Dynabead, mimicking in vivo stimulation by antigen
presenting cells as a model for alloimmune activation [55-57].
Freshly isolated CD19
+ magnetic-bead purified resting B cells were
resuspended in RPMI-1640 complete media to which anti-CD40
antibody (G28–5 anti-CD40mAb at 1 mg/ml) was added, followed
by cross-linking with goat-anti-mouse anti-IgG1 (STAR81, 0.2 mg/
ml). The cells were then cultured with rIL2 and rIL10 (100 ng/ml
each;Biosource)tosimulatetheT-celldependentB cellactivation of
an alloimmune response [12,58-65]. The cells were harvested and
total RNA was extracted at time 0, 24, 48 and 72 hours post
activation using the mirVana miRNA Isolation Kit (Ambion). The
mirVana protocol also allows for the isolation of the total proteome
fraction, which was collected for each time point and subsequently
used in the MudPIT proteomics (see later).
Analysis of Cell Activation by Multi-Channel Parallel Flow
Cytometry
Cell surface staining. Cells were resuspended in ice cold
PBE as follows: B and T cells for cell surface staining: 2610
6 cells/
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6 cells/mL. Cy5, Cy5.5
and Cy7-APC were coupled to individual monoclonal antibodies
and titrated antibody-dye reagents were combined into pre-made
cocktails. Cell suspension was added to 96-well plates and
incubated with antibody cocktails at room temperature in the
dark for 20 minutes. Buffer was added to each well to dilute
unbound antibodies and stained cells were analyzed with
SurroScan
TM cytometers (Pharmaceutical Product Development
(PPD), Inc, Menlo Park; http://www.ppdi.com/services/labs/
biomarker/surroscan.htm).
Intracellular staining. Cell surface staining steps are the
same except on ice and with washes. Cells are fixed with 0.5%
formaldehyde for 20 minutes at room temperature, then
permeabilized with 0.2% Saponin/5% FCS. Cells are incubated
with cytokine antibodies in 96 well plates at room temperature in
the dark for 20 minutes, followed by two washes with 0.2%
Saponin/5% FCS and resuspended in buffer for SurroScan
analysis.
Cell surface marker data analysis. A total of 1160 sample
assays were performed in parallel (T cells =62 assays618 samples
representing 9 donors at T0 and T48), B cells =18 assays 68
samples representing 8 donors all done at T48 of activation).
Standard gates were used in 90% of sample assays, non-standard
gates used in 10% sample assays. Invalid sample assays were only
0.4%. Data from invalid sample assays were excluded from
statistical analysis. Paired comparisons were performed for
stimulated vs. controls for T cell data. B cell analysis was
performed against PPD’s archived historical data for unstimulated
B cells (Tables S1 and S2).
Summary statistics on T cell data. Variable statistical
levels were designated S1, S2 and S3, where S1 represents primary
independent variables, S2 represents biologically meaningful but
redundant variables, and S3 represents biologically irrelevant
variables that were not considered. Step-down p-value adjustment
was used on S1 variables. The number of variables at each p-value
level are cumulative (See Table S8).
The GeneChipH Human Exon 1.0 ST Array Profiling
1.5 mg of total RNA per sample was converted into labeled cDNA
using the GeneChipH WT Sense Target Labeling kit (Affymetrix).
Labeled cDNA was hybridized to Affymetrix Human Exon 1.0 ST
arrays comprised of 1,404,693 probe sets that interrogate the whole
known human genome with 10 hybridizations performed on the
HumanExon1.0ST array per time point analysis (control vs. activated):
80 total =10 donors at 0, 24, 48, and 72 hrs for both T and B cells).
Data for mRNA transcript profiles were generated in the form of CEL
files using standard protocols (http://www.affymetrix.com/). The CEL
files obtained were analyzed using the XRAY software version
2.51 (Biotique; http://www.biotiquesystems.com/Products-Solutions/
XRAY//XRAY) to determine both differential as well as alternative
splicing profiles. The entire set of CEL files from this study are available
as Series GSE14352 at the NCBI Gene Expression Omnibus (GEO)
site.
XRAY Analysis of Gene Transcripts with Differential
Expression and Alternative Splicing Events
Data expression values were collected as individual CEL files for
each donor from the 1.0ST Exon Arrays and were then
normalized in XRAY (www.biotiquesystems.com) with full
quantile normalization. The 10 individual donors and 10
individual whole exon arrays (1 per donor) at each time point
were normalized as a single file in XRAY comprised of 10
individual CEL files. This was done for each of the 4 time points
(0, 24, 48 and 72 hours). These normalized, individual CEL files
were then analyzed in XRAY for changes as a function of time
after T or B cell activation. The normalized signal value data for
each gene represents the median signal of non-spliced exons for
that gene based on all 10 individuals. There were no technical
replicates done. In accordance with best statistical practices, a
linear model with Gaussian error was used to identify individual
expression differences and calculate error across the 10 CEL files
for each gene.
The normalized probe scores were pre-processed with back-
ground correction, probe summarization, and filtering of invariant
and non-expressed probe-sets. After pre-processing, the ‘‘Core’’
probe-sets (the probe-sets annotated by Affymetrix as based upon
the highest quality of genomic annotation) were analyzed with
Mixed Model Analysis of Variance (ANOVA) to identify
differential alternative splicing and/or differential expression.
The nested model is appropriate because data is not sampled in
a truly randomized fashion as expression points are harvested in
batches defined by hybridizations (or individual CEL files). The
mixed model is used since CEL files are random factors. The data
generated above are analyzed with Analysis of Variance (ANOVA)
according to the linear model:
Y i,j,l ½  ~ M z di ½ z ej ½ z cli ðÞ ½  z ed i,j ½  z ec j,l i ðÞ ½ 
where M is a global mean, d(i) is the effect attributable to tissue
state i, e(j) is the effect of exon j, and ec and ed are interaction
effects. c, which is the hybridization (or chip) effect, is a random
factor and all other factors are fixed. Note that the CEL file effect,
c, is nested inside tissue state. Genes with significant D (tissue)
effect are said to show significant tissue based gene expression
difference. Genes with significant Exon-Tissue interaction (ED
effect) are said to show signs of tissue specific alternative splicing
(p-value,0.001). Thus, differential gene expression was identified
as a significant) group effect (p-value,0.001) and alternative
splicing as a significant tissue-probeset interaction (p-val-
ue,0.001). For each gene XRAY tests the probability of a
‘false-positive’ as a p-value .0.001. Since each of the individual
gene tests are more or less independent tests and we are
conducting a large number of tests, this uncorrected significance
value could be misleading. The probability of finding a false-
positive will grow as more genes are tested. To correct for this
multiple testing challenge, we use the Benjamini and Hochberg
False Discovery Rate (FDR) method, where the gene-level p-values
are sorted in ascending order and then corrected. The sequential
step-down procedure described above was used to calculate that
the false discovery rate for this project is less than 1.00E+00 for
differential alternative splicing and gene expression tests. The
presence/absence of a gene in groups was assessed by deriving a p-
value to test the null hypothesis that the group probe-set
expression is not higher than the corresponding background
probes. Rejection of the null hypothesis occurs when the p-value is
less than the significance level of 0.001, in which case we infer that
the gene is most likely expressed in the given state (for a detailed
description of statistical calculations performed in XRAY, refer to
Methods S1). In the final step, genes that passed the filtering
criteria described here (i.e. expressed above background) and
demonstrated statistical significance for differential gene expres-
sion and alternative splicing after passing the FDR-corrected
ANOVA p-value,0.001 cut-off, were selected for further analysis.
Sample Preparation and Deep-Sequencing of RNA
The RNA-Seq library preparation and sequencing were
performed according to Illumina’s protocol (www.Illumina.com).
Specifically, 10 mg of total RNA, isolated from human T cells of a
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mRNA using oligo(dT)-magnetic beads. mRNA was fragmented
to 100–300 bp-sized pieces using divalent cations at 95uC. RNA
fragments were then copied into first strand cDNA using reverse
transcriptase and random primers. This was followed by second
strand cDNA synthesis using DNA Polymerase I and RNaseH.
These cDNA fragments then were subjected to an end repair
process, the addition of a single ‘A’ base, and then ligation of
Illumina sequencing adapters. The ligated products were run on
an agarose gel and a band was cut out of the gel corresponding to
an insert length of approximately 200 bases in length. This
product was then PCR amplified 12 cycles. The final sequencing
library was created from gel purification of this PCR product and
used directly for cluster generation and sequencing on an Illumina
GAII system according manufacturer’s instructions. Deep-
sequencing was used to generate 60 bp-reads from 3 replicate
lanes of a flowcell. The Genome Analyzer Pipeline Software
(Pipeline) was used to perform the early data analysis of the
sequencing run, including the image analysis, base calling, and
alignment. Alignment was performed with Efficient Large-Scale
Alignment of Nucleotide Databases (ELAND) which matches a
large number of reads against the human genome with no more
than two errors in the first 32 bases. Reads were mapped to the
human genome (hg18, National Center of Biotechnology Infor-
mation build 36.1).
Ingenuity Pathway Analysis
Ingenuity Pathways are based on a constantly curated database
of published literature on gene functions and interactions (https://
analysis.ingenuity.com). The data represent molecules and path-
ways that are presently known and published. One of the outputs
of Ingenuity analysis is functional pathways comprised of various
numbers of candidate genes. Ingenuity also identifies ‘‘node
genes’’ based on especially high degree of links to other genes in
known pathways. The genes predicted by XRAY analysis to be
significantly differentially expressed but not alternatively spliced
(DE p,0.001 and AS p.0.001), significantly alternatively spliced
and constitutively expressed (AS p,0.001 and DE p.0.001) and
both significantly differentially expressed and alternatively spliced
(DE p,0.001 and AS p,0.001) were used for Ingenuity Pathway
Analysis. Each set of genes identified by the gene symbol and
accompanied by either a fold-change for differential expression or
alternative splicing (AS), or both (DE+AS), was loaded into the
Ingenuity Pathway Analysis server to reveal biologically relevant
interactions for activated T and B cells.
Alternative Splice Validation by RT-PCR
Validation of alternative splicing was carried out by reverse
transcribing 1 mg of total RNA from 8 donor samples at 0 and
48 hours to cDNA using the SuperScript First-Strand Synthesis
System (Invitrogen) using random nonamer primers. PCR was
carried out for 40 cycles using Taq Polymerase (Roche) per
manufacturer’s instructions with 1 ml of 40-fold diluted cDNA
template. Primers were designed to adjacent constitutively
expressed exons, in some cases spanning a few flanking exons.
PCR products were separated on 2.5% high resolution Metaphor
agarose gels (Lonza) stained with ethidium bromide for visualiza-
tion. See Table S5 for primer sequences.
MudPIT Proteomics
We have used the Multi-dimensional Protein Identification Tool
(MudPIT) protocol as previously described [67] using an LTQ XL
mass spectrometer (ThermoFisher):
Sample preparation and data acquisition. Trizol was used
for protein isolation. Total protein was denatured, alkylated, and
trypsin digested as previously described[68]. 50 ug of digested protein
sample (BCA, Pierce) was used for each experiment. Each sample was
analyzed in four technical replicates. Mass spectrometry data were
acquired using an LTQ LX linear ion trap mass spectrometer
(ThermoFisher Scientific) interfaced in-line with 2D HPLC. The
chromatography was setup as MudPIT [69] where discreet fractions
from a front end strong cation exchange column were loaded onto and
eluted from a reversed phase analytical column. Each experiment
consisted of 14 discrete SCX fractions followed by a 130-minute linear
reverse phase gradient from 0 to 50% Acetonitrile (AcN). Sample was
introduced using nano-spray ESI at the flow rate of approximately
250 nl/min. The ESI voltage was held at 2.5 kV, and the capillary
temperature was set to 200uC. Data sets were acquired in a data-
dependant manner where each analytical full scan (MS, 200–2,000 m/
zunits range) was followed by three fragmentation scans (MS/MS) that
targeted the three most abundant ions from the full scan. 40-micro
second CID pulses of 35% intensity were used for precursor ion
fragmentation. A default exclusion list (Xcalibur 2.0, ThermoFisher
Scientific) of 180-second, 50 precursor ion members was used for data
acquisition.
Proteomic data analysis. Raw data were searched against
the EBI database (12/01/2006 release) supplemented with a decoy
database where each entry of the original protein contains its
reversed sequence. The database search was carried out using a
PBS parallelized version of SEQUEST (v27)[70]. Search
outcomes were post-processed and filtered using DTASelect [71]
version 2.0 (in preparation). DTASelect 2.0 uses a quadratic
discriminant analysis to dynamically adjust the XCorr and
DeltaCN parameters to meet a required false positive rate (set to
0.05). Protein identifications were extracted and a measure of
normalized amino acid coverage was used as label free
quantification. The exact formula used to calculate relative
protein abundance is as follows:
Aprotein~
P n
i~1
peptidei
P k
j~1
scanj
,
where Aprotein (protein abundance) is expressed as a ratio of the total
redundant peptide identifications per protein to the total number
of scans identified in the experiment. Each protein identification
was annotated by GO association [72] (Revision 1.59, www.
geneontology.org). Protein identifications across replicate
experiments were pooled to represent a union for each category
of 0 and 48-hour post activation. Proteins identified in two or more
technical replicates per category were kept for further analysis.
Relative protein abundance was compared between the 0 and the
48-hour post activation for proteins present in more than one
category. A two-tailed, independent Student’s t-test (pair-wise 0 vs.
48) was used for hypothesis testing (p-value cutoff of 0.05). Only
the significant differentially expressed proteins were considered for
functional analysis. Proteins identified in more than one technical
replicate in a single category and not in any category were also
considered for functional analysis as unique identifications.
Supporting Information
Figure S1 Activation analysis of stimulated and resting CD4+
and CD8+ T cells. A) From top to bottom: Intensity plots showing
levels of activation markers on CD4+ T cells and % of CD4+ T
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levels of chemokine receptors of CD4+ T cells and fraction of
stimulated CD4+ T cells positive for chemokine receptors.
Activation time point T48 or T0 hours is shown above the
corresponding box plots. Cells stimulated for 48 hours (T48) are
represented by clear box plots. Resting cells (T0) are represented
by gray box plots. Target antigen is shown below the box plot,
followed by the CYT-ID = a unique variable ID for each assay,
ACT/CTR = mean ratio of stimulated vs. control cells, Effect
Size = difference of means over SD, P-value = univariate P-value
(color coded). Refer to panel D for explanation of the Bar Graph
legends and P-value color codes. B) From top to bottom: Intensity
plots showing levels of activation markers on CD8+ T cells and %
of CD8+ T cells showing levels of activation markers. Intensity
plots showing levels of chemokine receptors of CD8+ T cells and
fraction of stimulated CD8+ T cells positive for chemokine
receptors. Activation time point T48 or T0 hours is shown above
the corresponding box plots. Cells stimulated for 48 hours (T48)
are represented by clear box plots. Resting cells (T0) are
represented by gray box plots. Target antigen is shown below
the box plot, followed by the CYT-ID = a unique variable ID for
each assay, ACT/CTR = mean ratio of stimulated vs. control
cells, Effect Size = difference of means over SD, P-value =
univariate P-value (color coded). Refer to panel D for explanation
of the Bar Graph legends and P-value color codes. C) From top to
bottom: CD127 (IL-7 receptor a chain) expression intensity for
CD4+ and CD8+ T cells at T48 and T0 hours. Fraction of CD4 +
T cells producing IFNc, IL-10, IL-2, IL-4, and TNFa. Fraction of
CD8+ T cells producing IFNc, IL-10, IL-2, IL-4, and TNFa.
Activation time point T48 or T0 hours is shown above the
corresponding box plots. Cells stimulated for 48 hours (T48) are
represented by clear box plots. Resting cells (T0) are represented
by gray box plots. Target antigen is shown below the box plots. D)
Graph legend. Cells stimulated for 48 hours (T48) are represented
by clear box plots. Resting cells (T0) are represented by gray box
plots. Variable statistics levels are represented by S1 (primary
independent variables), and S2 (biologically meaningful but
redundant variables). Step-down p-value adjustment was used on
S1 variables and the number of variables at each p-value level are
cumulative.
Found at: doi:10.1371/journal.pone.0007906.s001 (1.98 MB TIF)
Figure S2 Activation analysis of stimulated B cells at 48 hours
post activation. A) Intensity of stimulated B cells for activation
markers CD150 (SLAM), CD25 (IL-2Ra), and CD69 (early
activation marker). Only activated B cell data is shown. The
staining of resting B cells from archived PPD data show intensities
under 100 for this particular system using the SurroScan
technology. B) Fraction of activated B cells positive for the
activation markers. CYT-ID = unique variable ID for the assay,
Mean = mean %, SD = standard deviation. C) Intensity of co-
stimulatory molecule expression of CD54, CD80, CD86 for
activated B cells. D) % of activated B cells that are positive for co-
stimulatory molecules. E) Intensity and % of activated B cells that
express CD21 and CD62L that are shed during B cell activation.
Found at: doi:10.1371/journal.pone.0007906.s002 (0.96 MB TIF)
Table S1 CYT ID - Cytometry platform unique variable
identifier CYT - Cytometry Cell Type - Top level classification
of cell population Assay - The string consists of the target antigens
separated by underscores and arranged by the channel number
the reagent is measured on with SurroScan. Population -
Describes the specific cell population. Names are based on the
presence (p) or absences (n) of an individual antigen, e.g.
CD3pCD8p represents CD3 positive CD8 positive T cells, i.e.
CD8 T cells. A typical ASSAY may have 1 to 10 different
populations as Property - Is the identifier of the type of statistic
represented by the field VALUE such as COUNT (cells per uL) or
INTENSITY (relative). Count and intensity results are typically
generated for each POPULATION_NAME Count - Variable is
an absolute cell count Ratio - Ratio of two population counts
INTENSITY0 - Channel 0 intensity, the first antigen in assay
INTENSITY1 - Channel 1 intensity, the second antigen in assay
INTENSITY2 - Channel 2 intensity, the third antigen in assay
p - Presence or positive stain of an antigen, e.g. CD3p represents
CD3 positive T cells. n - Absences or negative stain of an antigen,
e.g. CD3pCD4n represents CD3 positive and CD4 negative T
cells. pn - Weaker positive in relative to stronger positive stain of
an antigen in same assay, e.g. CD45RBpn and CD45RBp
represent CD45RB dim and CD45RB bright population. SUM
- Add up the counts of two or more daughter populations to
obtain the counts of a parent population, e.g. the counts of
CD4pCD45RApCD62Ln and CD4pCD45RApCD62Lp popula-
tions are added up to get the counts of CD4pCD45RAp_SUM
population. Stat level - Output variables are classified into two
statistical categories forcomparativestatistical analysis.S1- primary
variable statistic used in reduced variable set form primary analysis.
S2 - secondary informative statistic biological useful represenation
[2log(p-value)] - Negative logarithm (base 10) of the p-value for the
given comparison Effectsize - Meandifferencebetween the groups/
weighted SD, presented as an absolute value Mean ratios. Ratio of
treated group to control group Mean - Mean for Cohort and
TimeType SD - Standard Deviation %CV - % Coefficient of
Variance (SD/Mean) AT - Activated T or B cells BC - Control T
cells.
Found at: doi:10.1371/journal.pone.0007906.s003 (0.16 MB
XLS)
Table S2 CYT ID - Cytometry platform unique variable
identifier CYT - Cytometry Cell Type - Top level classification
of cell population Assay - The string consists of the target antigens
separated by underscores and arranged by the channel number
the reagent is measured on with SurroScan. Population -
Describes the specific cell population. Names are based on the
presence (p) or absences (n) of an individual antigen, e.g.
CD3pCD8p represents CD3 positive CD8 positive T cells, i.e.
CD8 T cells. A typical ASSAY may have 1 to 10 different
populations Property - Is the identifier of the type of statistic
represented by the field VALUE such as COUNT (cells per uL) or
INTENSITY (relative). Count and intensity results are typically
generated for each POPULATION_NAME Count - Variable is
an absolute cell count Ratio - Ratio of two population counts
INTENSITY0 - Channel 0 intensity, the first antigen in assay
INTENSITY1 - Channel 1 intensity, the second antigen in assay
INTENSITY2 - Channel 2 intensity, the third antigen in assay p -
Presence or positive stain of an antigen, e.g. CD3p represents CD3
positive T cells. n - Absences or negative stain of an antigen, e.g.
CD3pCD4n represents CD3 positive and CD4 negative T cells.
pn - Weaker positive in relative to stronger positive stain of an
antigen in same assay, e.g. CD45RBpn and CD45RBp represent
CD45RB dim and CD45RB bright population. SUM - Add up the
counts of two or more daughter populations to obtain the counts of
a parent population, e.g. the counts of CD4pCD45RApCD62Ln
and CD4pCD45RApCD62Lp populations are added up to get the
counts of CD4pCD45RAp_SUM population. Stat level - Output
variables are classified into two statistical categories for compar-
ative statistical analysis. S1 - primary variable statistic used in
reduced variable set form primary analysis. S2 - secondary
informative statistic biological useful represen [2log(p-value)] -
Negative logarithm (base 10) of the p-value for the given
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weighted SD, presented as an absolute value Mean ratios Ratio of
treated group to control group Mean - Mean for Cohort and
TimeType SD - Standard Deviation %CV - % Coefficient of
Variance (SD/Mean) AT - Activated T or B cells BC - Control T
cells
Found at: doi:10.1371/journal.pone.0007906.s004 (0.39 MB
XLS)
Table S3
Found at: doi:10.1371/journal.pone.0007906.s005 (0.10 MB
DOC)
Table S4 Detected known or putative splice factors in T cells at
48 hrs post activation.
Found at: doi:10.1371/journal.pone.0007906.s006 (0.06 MB
DOC)
Table S5 *XRAY T48/T0 exon call - direction of splicing change,
activated vscontrol.*RNA Seq T48/T0 exon counts (3/3 samples)* -
change in exon counts, activated vs control. *Functiona prediction -
Proteins aligning or not aligning to the probeset. If the probe set is
downregulated, then the probeset is expressed more highly in the
control group. For example, (2)AA:1000(xxxxxxxx)R 1200(xxxxxx)
indicates that the shorter protein, with 1000 amino-acids is increased
in the experimental group. If the probeset is upregulated,(+)AA
indicates that the corresponding protein isoform is expressed more
highly in the activated group. (2)alt-X-terminus indicates that the
shorter isoform has a shorter terminus portion. (2)microRNA-target
indicateslossofpredictedmicroRNAbindingsites.*uniprot-Ensembl
feature predictions - Protein domains or functional regions increased
(+)or decreased (2)inthe experimentalgroup. *Ensembloverlapping
domains - reports overlaps between the identified probesets and the
functional domains from Ensemble InterPro IDs that have either
direct(indicatedby(direct),completealignment)orindirect(indicated
by (indirect), partial overlap, typically occur in the gene introns)
alignment between the probeset and domain genomic coordinates.
Found at: doi:10.1371/journal.pone.0007906.s007 (0.10 MB
XLS)
Table S6
Found at: doi:10.1371/journal.pone.0007906.s008 (1.37 MB
XLS)
Table S7
Found at: doi:10.1371/journal.pone.0007906.s009 (0.05 MB
XLS)
Table S8
Found at: doi:10.1371/journal.pone.0007906.s010 (0.01 MB
XLS)
Methods S1
Found at: doi:10.1371/journal.pone.0007906.s011 (0.09 MB
DOC)
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